PremiumThe FlyFusion announces first patient dosed in Phase 2 portion of AlphaBreak trial Fusion Pharmaceuticals Inc. Grapples with Tax Uncertainty: Potential Impacts on Finances and Investor Trust Largest borrow rate increases among liquid names PremiumThe FlyFusion Pharmaceuticals downgraded to Hold from Buy at TD Cowen Fusion Pharmaceuticals management to meet with Oppenheimer Fusion announces presentation of data from Phase 2 TATCIST clinical trial PremiumThe FlyWells Fargo downgraded, Best Buy upgraded: Wall Street’s top analyst calls Fusion Pharmaceuticals downgraded to Neutral from Buy at B. Riley Fusion Pharmaceuticals downgraded to Market Perform from Strong Buy at Raymond James 
